<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">63537</article-id><article-id pub-id-type="doi">10.7554/eLife.63537</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-211137"><name><surname>Goyal</surname><given-names>Ashish</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-63349"><name><surname>Reeves</surname><given-names>Daniel B</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5684-9538</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-211138"><name><surname>Cardozo-Ojeja</surname><given-names>E Fabian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-165403"><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2598-1621</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-184917"><name><surname>Mayer</surname><given-names>Bryan T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Vaccine and Infectious Disease Division</institution>, <institution>Fred Hutchinson Cancer Research Center</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Vaccine and Infectious Diseases</institution>, <institution>Fred Hutchinson Cancer Research Center</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-144423"><name><surname>Childs</surname><given-names>Lauren</given-names></name><role>Reviewing editor</role><aff/></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>jschiffe@fredhutch.org</email> (JS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>23</day><month>02</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e63537</elocation-id><history><date date-type="received"><day>28</day><month>09</month><year>2020</year></date><date date-type="accepted"><day>22</day><month>02</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Goyal et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Goyal et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-63537-v1.pdf"/><abstract><p>SARS-CoV-2 is difficult to contain because many transmissions occur during pre-symptomatic infection. Unlike influenza, most SARS-CoV-2 infected people do not transmit while a small percentage infect large numbers of people. We designed mathematical models which link observed viral loads with epidemiologic features of each virus, including distribution of transmissions attributed to each infected person and duration between symptom onset in the transmitter and secondarily infected person. We identify that people infected with SARS-CoV-2 or influenza can be highly contagious for less than one day, congruent with peak viral load. SARS-CoV-2 super-spreader events occur when an infected person is shedding at a very high viral load and has a high number of exposed contacts. The higher predisposition of SARS-CoV-2 towards super-spreading events cannot be attributed to additional weeks of shedding relative to influenza. Rather, a person infected with SARS-CoV-2 exposes more people within equivalent physical contact networks, likely due to aerosolization.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R01 AI121129-05S1</award-id><principal-award-recipient><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005663</institution-id><institution>Council of State and Territorial Epidemiologists</institution></institution-wrap></funding-source><award-id>Inform Public Health Decision Making Funding Opportunity</award-id><principal-award-recipient><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Joshua T Schiffer, Reviewing editor, <italic>eLife</italic>Is on the trial planning committee for a Gilead funded trial of remdesivir but is not reimbursed for this activity.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The original data and code is shared at: https://github.com/ashish2goyal/SARS_CoV_2_Super_Spreader_Event</p></sec><supplementary-material><ext-link xlink:href="elife-63537-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>